HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells <i>In Vitro</i> and <i>In Vivo</i>
Tri Nguyen(Virginia Commonwealth University), Steven Grant(Virginia Commonwealth University)
Cited by 76
Related Papers
Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation
|Journal of Biological Chemistry|2005|284
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
|Clinical Cancer Research|2009|230
The Bruton tyrosine kinase (<scp>BTK</scp>) inhibitor <scp>PCI</scp>‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (<scp>DLBCL</scp>) and mantle cell lymphoma (<scp>MCL</scp>) cells sensitive or resistant to bortezomib
|British Journal of Haematology|2013|84